Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 7/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.31 |
| ▸ | RXRA | P19793 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352192 | 0.88 | OPRM1 (0.33) | OPRM1OPRL1 | |
| SCHEMBL16860908 | 0.87 | PRNP (0.36) | AKR1B1TP53NR1H2RXRANR1H3 | |
| SCHEMBL5798506 | 0.80 | OPRM1 (0.41) | OPRM1OPRL1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL1222513 | 0.80 | OPRM1 (0.41) | OPRM1OPRL1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL3387388 | 0.74 | MC4R (0.40) | OPRM1OPRL1AKR1B1OPRK1PSEN1 | |
| SCHEMBL30413500 | 0.74 | OPRM1 (0.36) | OPRM1OPRL1PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL2354262 | 0.73 | HDAC2 (0.43) | SMN1; SMN2 | |
| SCHEMBL13837215 | 0.73 | AKR1B1 (0.35) | OPRM1OPRL1AKR1B1OPRK1PSEN1 | |
| SCHEMBL5579043 | 0.72 | OPRM1 (0.44) | OPRM1OPRL1AKR1B1TNKSTNKS2 | |
| SCHEMBL16086256 | 0.72 | USP30 (0.45) | TNKSTNKS2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598412-B2 | Spiroindoline compounds for use as anthelminthics | INTERVET INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150057302-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2015-02-26 | — | — | US | disclosed |
| EP-2531506-B1 | Spiroindoline compounds for use as anthelminthics | INTERVET INT BV (NL) | 2014-05-14 | — | — | EP | disclosed |
| EP-2531506-A1 | S PIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHI CS | Intervet International B.V. (NL) | 2012-12-12 | — | — | EP | disclosed |
| US-20120295931-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | INTERVET INC. | 2012-11-22 | — | — | US | disclosed |
| WO-2011095581-A1 | S PIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHI CS | INTERVET INTERNATIONAL B.V. (NL) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057302-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | PKD2, PKD1, PIR | OPRM1 3437/4885OPRL1 715/4885AKR1B1 158/4885 |
| US-20120295931-A1 | SPIROINDOLINE COMPOUNDS FOR USE AS ANTHELMINTHICS | PKD2, PKD1, PIR | OPRM1 3437/4885OPRL1 715/4885AKR1B1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.